Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has conseque...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2010-08-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1424-8247/3/8/2441/ |
| _version_ | 1811285403105230848 |
|---|---|
| author | Roberto Pili Leigh Ellis |
| author_facet | Roberto Pili Leigh Ellis |
| author_sort | Roberto Pili |
| collection | DOAJ |
| description | Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents. |
| first_indexed | 2024-04-13T02:43:34Z |
| format | Article |
| id | doaj.art-e907fd9754c94d7f8673516807ca2670 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-04-13T02:43:34Z |
| publishDate | 2010-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-e907fd9754c94d7f8673516807ca26702022-12-22T03:06:07ZengMDPI AGPharmaceuticals1424-82472010-08-01382441246910.3390/ph3082441Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid MalignanciesRoberto PiliLeigh EllisAdvancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents.http://www.mdpi.com/1424-8247/3/8/2441/cancerepigeneticsepigenetic therapyHDACHDAC inhibitorsapoptosisangiogenesisautophagypre-clinicalclinical trial |
| spellingShingle | Roberto Pili Leigh Ellis Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies Pharmaceuticals cancer epigenetics epigenetic therapy HDAC HDAC inhibitors apoptosis angiogenesis autophagy pre-clinical clinical trial |
| title | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
| title_full | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
| title_fullStr | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
| title_full_unstemmed | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
| title_short | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
| title_sort | histone deacetylase inhibitors advancing therapeutic strategies in hematological and solid malignancies |
| topic | cancer epigenetics epigenetic therapy HDAC HDAC inhibitors apoptosis angiogenesis autophagy pre-clinical clinical trial |
| url | http://www.mdpi.com/1424-8247/3/8/2441/ |
| work_keys_str_mv | AT robertopili histonedeacetylaseinhibitorsadvancingtherapeuticstrategiesinhematologicalandsolidmalignancies AT leighellis histonedeacetylaseinhibitorsadvancingtherapeuticstrategiesinhematologicalandsolidmalignancies |